Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

teniposide

A semisynthetic derivative of podophyllotoxin with antineoplastic activity. Teniposide forms a ternary complex with the enzyme topoisomerase II and DNA, resulting in dose-dependent single- and double-stranded breaks in DNA, DNA: protein cross-links, inhibition of DNA strand religation, and cytotoxicity. This agent acts in the late S or early G phase of the cell cycle.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Thenvlidene-Lignan-P
Thenylidene-Lignan-P
VM26
US brand name:Vumon
Foreign brand name:Vehem
Abbreviation:EPT
PTG
Code name:VM-26
Chemical structure:[5R-[5Alpha,5a beta,8a alpha, 9beta(R*)]]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-beta-D-glucopyranosyl]oxy]furo[3',4':6,7]-naphtho[2,3-d]-1,3-dioxol-6(5aH)-one
4'-Demethylepipodophyllotoxin 9-(4,6-O-2-Thenylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin-beta-D-thenylidine Glucoside
IND number:9336
NSC code:122819
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search